PharmaCyte Biotech (PMCB) Preferred Stock Liabilities (2023 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Preferred Stock Liabilities of $1.3 million for Q2 2026, up 45.46% quarter-over-quarter from $872323.0 in Q1 2026.
PharmaCyte Biotech (PMCB) Preferred Stock Liabilities (2023 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Preferred Stock Liabilities for 4 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Preferred Stock Liabilities changed N/A year-over-year to $1.3 million; the TTM figure through Apr 2026 stood at $1.3 million (changed N/A YoY), while the FY2026 annual figure was $1.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities rose to $1.3 million in Q2 2026 per PMCB's latest filing, from $872323.0 in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $21.3 million in Q4 2023 and bottomed at $872323.0 in Q1 2026.
- Historically, Preferred Stock Liabilities has averaged $9.5 million across 4 years, with a median of $8.6 million in 2024.
- On a YoY basis, Preferred Stock Liabilities climbed as much as 68.17% in 2024 and fell as far as 68.17% in 2024.
- PharmaCyte Biotech's Preferred Stock Liabilities stood at $21.3 million in 2023, then sank by 74.96% to $5.3 million in 2024, then tumbled by 83.09% to $901996.0 in 2025, then soared by 40.68% to $1.3 million in 2026.
- Business Quant data shows PMCB's Preferred Stock Liabilities at $1.3 million in Q2 2026, $872323.0 in Q1 2026, and $901996.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | 1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1.27 Mn |
| Jan 31, 2026 | 872,323.00 |
| Oct 31, 2025 | 901,996.00 |
| Jul 31, 2024 | 5.33 Mn |
| Apr 30, 2024 | 11.87 Mn |
| Jan 31, 2024 | 17.52 Mn |
| Oct 31, 2023 | 21.30 Mn |
| Jul 31, 2023 | 16.75 Mn |